Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus BLOXIVERZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus BLOXIVERZ.
ARICEPT vs BLOXIVERZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
BLOXIVERZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the serotonin transporter (SERT), leading to increased extracellular serotonin levels.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
10 mg intravenously every 12 hours; may increase to 15 mg every 12 hours based on clinical response.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal half-life 18 hours (range 14-22 h); clinical: steady state in ~3.5 days, dosing adjustments needed in renal impairment.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other routes.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor